The stock of Tonix Pharmaceuticals Holding Corp (TNXP) has seen a 12.10% increase in the past week, with a -51.51% drop in the past month, and a -50.18% decrease in the past quarter. The volatility ratio for the week is 11.41%, and the volatility levels for the past 30 days are at 17.18% for TNXP. The simple moving average for the last 20 days is -6.93% for TNXP stock, with a simple moving average of -87.41% for the last 200 days.
Is It Worth Investing in Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Right Now?
Company’s 36-month beta value is 2.24.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNXP is 5.59M, and currently, short sellers hold a 5.97% ratio of that floaft. The average trading volume of TNXP on March 05, 2025 was 1.61M shares.
TNXP) stock’s latest price update
The stock of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has increased by 21.15 when compared to last closing price of 7.80. Despite this, the company has experienced a 12.10% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-05 that CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the 2025 Virtual Investor Summit on Tuesday, March 11, 2025, at 10:30 a.m.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at -60.84% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.22% of loss for the given period.
Volatility was left at 17.18%, however, over the last 30 days, the volatility rate increased by 11.41%, as shares sank -38.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -74.45% lower at present.
During the last 5 trading sessions, TNXP rose by +10.56%, which changed the moving average for the period of 200-days by -98.40% in comparison to the 20-day moving average, which settled at $10.15. In addition, Tonix Pharmaceuticals Holding Corp saw -71.35% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -7.31 for the present operating margin
- 0.08 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -11.98. The total capital return value is set at -1.03. Equity return is now at value -138.69, with -115.46 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -11.5.
Currently, EBITDA for the company is -114.09 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 2.63. The receivables turnover for the company is 2.81for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.33.
Conclusion
In a nutshell, Tonix Pharmaceuticals Holding Corp (TNXP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
